PEG interferon (combined) · patients on HD with HCV infection
High showed no clear difference in PEG interferon (combined) compared with low dose pegylated interferon alpha‐2a or alpha‐2b (moderate certainty).
3 findings from 1 review
RR 4.3 [0.76, 24.33]
2 studies · 97 participants
Moderate
RR 1.12 [0.4, 2.21]
1 study · 43 participants
Low
RR 1.05 [0.61, 1.83]
2 studies · 97 participants
Moderate
End‐of‐treatment response · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sustained virological response · patients on HD with HCV infection
It is very uncertain whether pegylated interferon + ribavirin (24 weeks) + initial telepravir (12… changes sustained virological response compared with pegylated interferon (48 weeks) + initial telepravir (12 weeks) +… (very low certainty).
1 finding from 1 review
End‐of‐treatment response · patients on HD with HCV infection
It is very uncertain whether pegylated interferon + ribavirin (24 weeks) + initial telepravir (12… changes end‐of‐treatment response compared with pegylated interferon (48 weeks) + initial telepravir (12 weeks) +… (very low certainty).
1 finding from 1 review
Treatment discontinuation · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Eclampsia · women with pre‐eclampsia
1 finding from 1 review
Eclampsia: 2 g per hour IV maintenance versus 1 g per hour IV maintenance · women with pre‐eclampsia
1 finding from 1 review
Eclampsia: 2 g per hour IV versus weight‐adjusted maintenance dose · women with pre‐eclampsia
1 finding from 1 review
Severe morbidity · women with pre‐eclampsia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Side effects · women with pre‐eclampsia
Prevention of eclampsia: higher showed no clear difference in side effects compared with lower IV maintenance regimen (low certainty).
1 finding from 1 review
Death of baby (up to discharge) · women with pre‐eclampsia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maternal death · women with pre‐eclampsia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other neonatal morbidity · women with pre‐eclampsia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in symptoms · GORD in children over 1 year of age
1 finding from 1 review